Cytochrome P450 CYP1B1 activity in renal cell carcinoma

M C E McFadyen, W T Melvin, G I Murray

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is the most common malignancy of the kidney and has a poor prognosis due to its late presentation and resistance to current anticancer drugs. One mechanism of drug resistance, which is potentially amenable to therapeutic intervention, is based on studies in our laboratory. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours. Our studies are now elucidating a functional role for CYP1B1 in drug resistance. Cytochrome P450 reductase (P450R) is required for optimal metabolic activity of CYP1B1. Both CYP1B1 and P450R can catalyse the biotransformation of anticancer drugs at the site of the tumour. In this investigation, we determined the expression of CYP1B1 and P450R in samples of normal kidney and RCC (11 paired normal and tumour and a further 15 tumour samples). The O-deethylation of ethoxyresorufin to resorufin was used to measure CYP1B1 activity in RCC. Cytochrome P450 reductase activity was determined by following the reduction of cytochrome c at 550 nm. The key finding of this study was the presence of active CYP1B1 in 70% of RCC. Coincubation with the CYP1B1 inhibitor alpha-naphthoflavone (10 nM) inhibited this activity. No corresponding CYP1B1 activity was detected in any of the normal tissue examined (n=11). Measurable levels of active P450R were determined in all normal (n=11) and tumour samples (n=26). The presence of detectable CYP1B1, which is capable of metabolising anticancer drugs in tumour cells, highlights a novel target for therapeutic intervention.

Original languageEnglish
Pages (from-to)966-971
Number of pages6
JournalBritish Journal of Cancer
Volume91
DOIs
Publication statusPublished - 2004

Keywords

  • CYP1B1
  • P450 reductase
  • renal cell carcinoma
  • tumour
  • therapeutic intervention
  • LIVER-MICROSOMES
  • IN-VITRO
  • METABOLIC-ACTIVATION
  • OMEGA-HYDROXYLATION
  • DRUG-RESISTANCE
  • P450 REDUCTASE
  • EXPRESSION
  • CANCER
  • P450CYP1B1
  • 1B1

Cite this

Cytochrome P450 CYP1B1 activity in renal cell carcinoma. / McFadyen, M C E ; Melvin, W T ; Murray, G I .

In: British Journal of Cancer, Vol. 91, 2004, p. 966-971.

Research output: Contribution to journalArticle

McFadyen, M C E ; Melvin, W T ; Murray, G I . / Cytochrome P450 CYP1B1 activity in renal cell carcinoma. In: British Journal of Cancer. 2004 ; Vol. 91. pp. 966-971.
@article{ee18ddc1ea754ccbb6c81cae003cd33c,
title = "Cytochrome P450 CYP1B1 activity in renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is the most common malignancy of the kidney and has a poor prognosis due to its late presentation and resistance to current anticancer drugs. One mechanism of drug resistance, which is potentially amenable to therapeutic intervention, is based on studies in our laboratory. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours. Our studies are now elucidating a functional role for CYP1B1 in drug resistance. Cytochrome P450 reductase (P450R) is required for optimal metabolic activity of CYP1B1. Both CYP1B1 and P450R can catalyse the biotransformation of anticancer drugs at the site of the tumour. In this investigation, we determined the expression of CYP1B1 and P450R in samples of normal kidney and RCC (11 paired normal and tumour and a further 15 tumour samples). The O-deethylation of ethoxyresorufin to resorufin was used to measure CYP1B1 activity in RCC. Cytochrome P450 reductase activity was determined by following the reduction of cytochrome c at 550 nm. The key finding of this study was the presence of active CYP1B1 in 70{\%} of RCC. Coincubation with the CYP1B1 inhibitor alpha-naphthoflavone (10 nM) inhibited this activity. No corresponding CYP1B1 activity was detected in any of the normal tissue examined (n=11). Measurable levels of active P450R were determined in all normal (n=11) and tumour samples (n=26). The presence of detectable CYP1B1, which is capable of metabolising anticancer drugs in tumour cells, highlights a novel target for therapeutic intervention.",
keywords = "CYP1B1, P450 reductase, renal cell carcinoma, tumour, therapeutic intervention, LIVER-MICROSOMES, IN-VITRO, METABOLIC-ACTIVATION, OMEGA-HYDROXYLATION, DRUG-RESISTANCE, P450 REDUCTASE, EXPRESSION, CANCER, P450CYP1B1, 1B1",
author = "McFadyen, {M C E} and Melvin, {W T} and Murray, {G I}",
year = "2004",
doi = "10.1038/sj.bjc.6602053",
language = "English",
volume = "91",
pages = "966--971",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Cytochrome P450 CYP1B1 activity in renal cell carcinoma

AU - McFadyen, M C E

AU - Melvin, W T

AU - Murray, G I

PY - 2004

Y1 - 2004

N2 - Renal cell carcinoma (RCC) is the most common malignancy of the kidney and has a poor prognosis due to its late presentation and resistance to current anticancer drugs. One mechanism of drug resistance, which is potentially amenable to therapeutic intervention, is based on studies in our laboratory. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours. Our studies are now elucidating a functional role for CYP1B1 in drug resistance. Cytochrome P450 reductase (P450R) is required for optimal metabolic activity of CYP1B1. Both CYP1B1 and P450R can catalyse the biotransformation of anticancer drugs at the site of the tumour. In this investigation, we determined the expression of CYP1B1 and P450R in samples of normal kidney and RCC (11 paired normal and tumour and a further 15 tumour samples). The O-deethylation of ethoxyresorufin to resorufin was used to measure CYP1B1 activity in RCC. Cytochrome P450 reductase activity was determined by following the reduction of cytochrome c at 550 nm. The key finding of this study was the presence of active CYP1B1 in 70% of RCC. Coincubation with the CYP1B1 inhibitor alpha-naphthoflavone (10 nM) inhibited this activity. No corresponding CYP1B1 activity was detected in any of the normal tissue examined (n=11). Measurable levels of active P450R were determined in all normal (n=11) and tumour samples (n=26). The presence of detectable CYP1B1, which is capable of metabolising anticancer drugs in tumour cells, highlights a novel target for therapeutic intervention.

AB - Renal cell carcinoma (RCC) is the most common malignancy of the kidney and has a poor prognosis due to its late presentation and resistance to current anticancer drugs. One mechanism of drug resistance, which is potentially amenable to therapeutic intervention, is based on studies in our laboratory. CYP1B1 is a cytochrome P450 enzyme overexpressed in a variety of malignant tumours. Our studies are now elucidating a functional role for CYP1B1 in drug resistance. Cytochrome P450 reductase (P450R) is required for optimal metabolic activity of CYP1B1. Both CYP1B1 and P450R can catalyse the biotransformation of anticancer drugs at the site of the tumour. In this investigation, we determined the expression of CYP1B1 and P450R in samples of normal kidney and RCC (11 paired normal and tumour and a further 15 tumour samples). The O-deethylation of ethoxyresorufin to resorufin was used to measure CYP1B1 activity in RCC. Cytochrome P450 reductase activity was determined by following the reduction of cytochrome c at 550 nm. The key finding of this study was the presence of active CYP1B1 in 70% of RCC. Coincubation with the CYP1B1 inhibitor alpha-naphthoflavone (10 nM) inhibited this activity. No corresponding CYP1B1 activity was detected in any of the normal tissue examined (n=11). Measurable levels of active P450R were determined in all normal (n=11) and tumour samples (n=26). The presence of detectable CYP1B1, which is capable of metabolising anticancer drugs in tumour cells, highlights a novel target for therapeutic intervention.

KW - CYP1B1

KW - P450 reductase

KW - renal cell carcinoma

KW - tumour

KW - therapeutic intervention

KW - LIVER-MICROSOMES

KW - IN-VITRO

KW - METABOLIC-ACTIVATION

KW - OMEGA-HYDROXYLATION

KW - DRUG-RESISTANCE

KW - P450 REDUCTASE

KW - EXPRESSION

KW - CANCER

KW - P450CYP1B1

KW - 1B1

U2 - 10.1038/sj.bjc.6602053

DO - 10.1038/sj.bjc.6602053

M3 - Article

VL - 91

SP - 966

EP - 971

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -